To view this content, you need to sign in.
You should only be asked to sign in once. Not the case? Click here
Register now to access this content and more for free.
THL investment values Bazaarvoice at $1.5b-plus, Ares gains secondaries business through $1b Landmark acquisition, Avista sees opportunity to simplify early-stage drug-development
THL's investment in Bazaarvoice puts company at an over $1.5 billion valuation and Ares agrees to buy secondaries shop Landmark Partners.
